Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46


Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases.

Owen DR, Wong HL, Bonakdar M, Jones M, Hughes CS, Morin GB, Jones SJM, Renouf DJ, Lim H, Laskin J, Marra M, Yip S, Schaeffer DF.

Cold Spring Harb Mol Case Stud. 2018 Feb 8. pii: mcs.a002535. doi: 10.1101/mcs.a002535. [Epub ahead of print]


Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Jan 22. doi: 10.1158/1078-0432.CCR-17-2810. [Epub ahead of print]


Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.


Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

Jones MR, Lim H, Shen Y, Pleasance E, Ch'ng C, Reisle C, Leelakumari S, Zhao C, Yip S, Ho J, Zhong E, Ng T, Ionescu D, Schaeffer DF, Mungall AJ, Mungall KL, Zhao Y, Moore RA, Ma Y, Chia S, Ho C, Renouf DJ, Gelmon K, Jones SJM, Marra MA, Laskin J.

Ann Oncol. 2017 Dec 1;28(12):3092-3097. doi: 10.1093/annonc/mdx523.


Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.

Tessier-Cloutier B, Kalloger SE, Al-Kandari M, Milne K, Gao D, Nelson BH, Renouf DJ, Sheffield BS, Schaeffer DF.

BMC Cancer. 2017 Sep 5;17(1):618. doi: 10.1186/s12885-017-3634-5.


A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.

Kalloger SE, Riazy M, Tessier-Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong HL, Mackey JR, Renouf DJ, Schaeffer DF.

J Pathol Clin Res. 2017 Jul 19;3(3):179-190. doi: 10.1002/cjp2.75. eCollection 2017 Jul.


The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Weymann D, Laskin J, Roscoe R, Schrader KA, Chia S, Yip S, Cheung WY, Gelmon KA, Karsan A, Renouf DJ, Marra M, Regier DA.

Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.


Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.


Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.

Korpanty GJ, Eng L, Qiu X, Faluyi OO, Renouf DJ, Cheng D, Patel D, Chen Z, Tse BC, Knox JJ, Dodbiba L, Teichman J, Azad AK, Wong R, Darling G, Reisman D, Cuffe S, Liu G, Xu W.

Oncotarget. 2017 Apr 25;8(17):28093-28100. doi: 10.18632/oncotarget.15890.


Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.

Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G.

Cancer Med. 2017 Feb;6(2):361-373. doi: 10.1002/cam4.989. Epub 2017 Jan 11.


Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study.

Sheffield BS, Tessier-Cloutier B, Li-Chang H, Shen Y, Pleasance E, Kasaian K, Li Y, Jones SJ, Lim HJ, Renouf DJ, Huntsman DG, Yip S, Laskin J, Marra M, Schaeffer DF.

Curr Oncol. 2016 Dec;23(6):e571-e575. doi: 10.3747/co.23.3165. Epub 2016 Dec 21.


Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer.

Ho MY, Renouf DJ, Cheung WY, Lim HJ, Speers CH, Zhou C, Kennecke HF.

Curr Oncol. 2016 Oct;23(5):329-333. Epub 2016 Oct 25.


A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer.

Lee-Ying R, Bernard B, Gresham G, Chen L, Speers C, Kennecke HF, Lim HJ, Cheung WY, Renouf DJ.

Clin Colorectal Cancer. 2017 Jun;16(2):e23-e28. doi: 10.1016/j.clcc.2016.07.018. Epub 2016 Aug 9.


A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.

Renouf DJ, Hedley D, Krzyzanowska MK, Schmuck M, Wang L, Moore MJ.

Cancer Chemother Pharmacol. 2016 Sep;78(3):541-5. doi: 10.1007/s00280-016-3102-y. Epub 2016 Jul 15.


Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.

Loree JM, Kennecke HF, Renouf DJ, Lim HJ, Vickers MM, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2016 Dec;15(4):352-359.e1. doi: 10.1016/j.clcc.2016.04.003. Epub 2016 May 7.


Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

Jones MR, Schrader KA, Shen Y, Pleasance E, Ch'ng C, Dar N, Yip S, Renouf DJ, Schein JE, Mungall AJ, Zhao Y, Moore R, Ma Y, Sheffield BS, Ng T, Jones SJ, Marra MA, Laskin J, Lim HJ.

Ann Oncol. 2016 May;27(5):801-6. doi: 10.1093/annonc/mdw060. Epub 2016 Feb 18.


A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL.

Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19.


Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, Speers C, Cheung WY.

Clin Colorectal Cancer. 2016 Jun;15(2):179-85. doi: 10.1016/j.clcc.2015.09.002. Epub 2015 Sep 30.


Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, Nostro C, Wang R, Muthuswamy LB, Crawford HC, Arrowsmith C, Kalloger SE, Renouf DJ, Connor AA, Cleary S, Schaeffer DF, Roehrl M, Tsao MS, Gallinger S, Keller G, Muthuswamy SK.

Nat Med. 2015 Nov;21(11):1364-71. doi: 10.1038/nm.3973. Epub 2015 Oct 26.


Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes.

Vergidis J, Gresham G, Lim HJ, Renouf DJ, Kennecke HF, Ruan JY, Chang JT, Cheung WY.

Clin Colorectal Cancer. 2016 Mar;15(1):16-23. doi: 10.1016/j.clcc.2015.07.002. Epub 2015 Jul 26.


Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.

Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF.

Mod Pathol. 2015 Oct;28(10):1383-9. doi: 10.1038/modpathol.2015.89. Epub 2015 Jul 31.


Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT, Cheung WY.

Support Care Cancer. 2016 Feb;24(2):799-805. doi: 10.1007/s00520-015-2846-y. Epub 2015 Jul 17.


Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.

Ho MY, Kennecke HF, Renouf DJ, Cheung WY, Lim HJ, Gill S.

Am J Clin Oncol. 2017 Dec;40(6):552-554. doi: 10.1097/COC.0000000000000205.


Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2015 Dec;14(4):262-8.e1. doi: 10.1016/j.clcc.2015.05.010. Epub 2015 Jun 6.


Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.

Eng L, Azad AK, Qiu X, Kong QQ, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Liu G, Faluyi OO.

Carcinogenesis. 2015 Sep;36(9):956-62. doi: 10.1093/carcin/bgv073. Epub 2015 May 25.


Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.

Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF.

Cancer Med. 2015 Aug;4(8):1171-7. doi: 10.1002/cam4.459. Epub 2015 Apr 18.


Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.

Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, Cheung WY.

Am J Clin Oncol. 2017 Oct;40(5):507-511. doi: 10.1097/COC.0000000000000193.


Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.

O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF.

Am J Surg Pathol. 2015 Apr;39(4):472-8. doi: 10.1097/PAS.0000000000000333.


Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.

Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY.

Cancer. 2015 Feb 15;121(4):527-34. doi: 10.1002/cncr.29072. Epub 2014 Oct 20.


Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.

Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ.

J Gastrointest Oncol. 2014 Aug;5(4):259-64. doi: 10.3978/j.issn.2078-6891.2014.036.


Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.

Gresham G, Renouf DJ, Chan M, Kennecke HF, Lim HJ, Brown C, Cheung WY.

Ann Surg Oncol. 2014 Nov;21(12):3917-23. doi: 10.1245/s10434-014-3797-0. Epub 2014 May 24.


A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ.

Eur J Cancer. 2014 Jul;50(11):1909-15. doi: 10.1016/j.ejca.2014.04.008. Epub 2014 May 21.


Diagnostic value of next-generation sequencing in an unusual sphenoid tumor.

Jamshidi F, Pleasance E, Li Y, Shen Y, Kasaian K, Corbett R, Eirew P, Lum A, Pandoh P, Zhao Y, Schein JE, Moore RA, Rassekh R, Huntsman DG, Knowling M, Lim H, Renouf DJ, Jones SJ, Marra MA, Nielsen TO, Laskin J, Yip S.

Oncologist. 2014 Jun;19(6):623-30. doi: 10.1634/theoncologist.2013-0390. Epub 2014 May 7.


Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.

Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, Li S, Christiani DC, Liu G.

J Gastroenterol Hepatol. 2013 Sep;28(9):1482-8. doi: 10.1111/jgh.12286.


Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment.

Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, Bristow RG, Tsao MS, Darling GE, Ailles LE, El-Zimaity H, Liu G.

Lab Invest. 2013 Apr;93(4):397-407. doi: 10.1038/labinvest.2013.8. Epub 2013 Feb 11.


Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.

Alipour S, Kennecke HF, Woods R, Lim HJ, Speers C, Brown CJ, Gill S, Renouf DJ, Cheung WY.

J Gastrointest Cancer. 2013 Jun;44(2):203-10. doi: 10.1007/s12029-012-9472-4.


Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer.

Renouf DJ, Woods R, Speers C, Hay J, Phang PT, Fitzgerald C, Kennecke H.

Am J Clin Oncol. 2013 Dec;36(6):558-64. doi: 10.1097/COC.0b013e318256f5dc.


Ocular toxicity of targeted therapies.

Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL.

J Clin Oncol. 2012 Sep 10;30(26):3277-86. doi: 10.1200/JCO.2011.41.5851. Epub 2012 May 29. Review.


A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.

Renouf DJ, Welch S, Moore MJ, Krzyzanowska MK, Knox J, Feld R, Liu G, MacKay H, Petronis J, Wang L, Chen E.

Cancer Chemother Pharmacol. 2012 May;69(5):1339-44. doi: 10.1007/s00280-012-1843-9. Epub 2012 Feb 15.


Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.

Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S.

Eur J Cancer. 2012 Sep;48(13):1969-76. doi: 10.1016/j.ejca.2012.01.012. Epub 2012 Feb 9.


Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

Renouf DJ, Lim HJ, Speers C, Villa D, Gill S, Blanke CD, O'Reilly SE, Kennecke H.

Clin Colorectal Cancer. 2011 Jun;10(2):97-101. doi: 10.1016/j.clcc.2011.03.004. Epub 2011 Apr 22.


A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ.

Invest New Drugs. 2012 Jun;30(3):1203-7. doi: 10.1007/s10637-011-9673-x. Epub 2011 Apr 28.


A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.

Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L.

Invest New Drugs. 2012 Apr;30(2):779-86. doi: 10.1007/s10637-010-9611-3. Epub 2010 Dec 18.


Surgical oncology: Is PBD suitable for resectable pancreatic cancer?

Renouf DJ, Moore MJ.

Nat Rev Clin Oncol. 2010 May;7(5):246-7. doi: 10.1038/nrclinonc.2010.46. No abstract available.


Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.

Renouf DJ, Wilson L, Blanke CD.

Clin Cancer Res. 2009 Jun 15;15(12):3908-11. doi: 10.1158/1078-0432.CCR-08-1622. Epub 2009 Jun 9.


BCL-2 expression is prognostic for improved survival in non-small cell lung cancer.

Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J.

J Thorac Oncol. 2009 Apr;4(4):486-91. doi: 10.1097/JTO.0b013e318199e03a.

Supplemental Content

Loading ...
Support Center